Filtered By:
Specialty: Internal Medicine
Source: Journal of Internal Medicine
Drug: Pradaxa

This page shows you your search results in order of date.

Order by Relevance | Date

Total 6 results found since Jan 2013.

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE ‐LY trial
ConclusionsAmongst the current clinical bleeding risk scores, the ORBIT score demonstrated the best discrimination and calibration. All the scores demonstrated, to a variable extent, an interaction with bleeding risk associated with dabigatran or warfarin.
Source: Journal of Internal Medicine - November 7, 2017 Category: Internal Medicine Authors: M. Proietti, Z. Hijazi, U. Andersson, S. J. Connolly, J. W. Eikelboom, M. D. Ezekowitz, D. A. Lane, J. Oldgren, V. Roldan, S. Yusuf, L. Wallentin, Tags: Original Article Source Type: research

Comparison of Bleeding Risk Scores in Patients with Atrial Fibrillation:Insights from the RE ‐LY Trial
ConclusionsAmong the current clinical bleeding risk scores, the ORBIT score demonstrated the best discrimination and calibration. All the scores demonstrated, to a variable extent, an interaction with bleeding risk associated with dabigatran or warfarin.This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - October 16, 2017 Category: Internal Medicine Authors: Marco Proietti, Ziad Hijazi, Ulrika Andersson, Stuart J Connolly, John W Eikelboom, Michael D Ezekowitz, Deirdre A. Lane, Jonas Oldgren, Vanessa Roldan, Salim Yusuf, Lars Wallentin, Tags: Original Source Type: research

Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
ConclusionsStandard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.
Source: Journal of Internal Medicine - September 21, 2017 Category: Internal Medicine Authors: L. Staerk, T. A. Gerds, G. Y. H. Lip, B. Ozenne, A. N. Bonde, M. Lamberts, E. L. Fosb øl, C. Torp‐Pedersen, G. H. Gislason, J. B. Olesen Tags: Original Article Source Type: research

Important factors affecting the choice of an oral anticoagulant may be missed in database studies
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - September 7, 2017 Category: Internal Medicine Authors: Emma Aarnio, Risto Huupponen, Maarit Jaana Korhonen Tags: Letter to the Editor Source Type: research

Standard and reduced doses of dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
ConclusionsStandard and reduced dose NOACs, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban, and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - September 1, 2017 Category: Internal Medicine Authors: Laila Staerk, Thomas A Gerds, Gregory Y H Lip, Brice Ozenne, Anders N Bonde, Morten Lamberts, Emil L Fosb øl, Christian Torp‐Pedersen, Gunnar H Gislason, Jonas B Olesen Tags: Original Article Source Type: research

Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
ConclusionsAF patients who were initiated on apixaban had higher stroke risk scores than patients initiated on VKAs. Interestingly, opposite results were found for dabigatranThis article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - May 8, 2017 Category: Internal Medicine Authors: Anna Gundlund, Laila Staerk, Emil Loldrup Fosb øl, Kasper Gadsboel, Caroline Sindet‐Pedersen, Anders Nissen Bonde, Gunnar H. Gislason, Jonas Bjerring Olesen Tags: Original Source Type: research